Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21779737 | 0.91 | KDM4E (0.37) | KDM4EALDH1A1GAAHPGDSMN1; SMN2 | |
| SCHEMBL765004 | 0.84 | — | — | |
| SCHEMBL1962749 | 0.84 | — | — | |
| SCHEMBL14137797 | 0.81 | KDM4E (0.41) | KDM4EALDH1A1GAAHPGDSMN1; SMN2 | |
| SCHEMBL19982905 | 0.81 | KDM4E (0.41) | KDM4EALDH1A1GAAHPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28794792 | 0.80 | APLNR (0.36) | KDM4EALDH1A1GAAHPGDSMN1; SMN2 | |
| SCHEMBL26259604 | 0.79 | KDM4E (0.39) | KDM4EALDH1A1GAAHPGDSMN1; SMN2 | |
| SCHEMBL178385 | 0.79 | CYP1A2 (0.36) | ALDH1A1 | |
| SCHEMBL25792748 | 0.79 | KDM4E (0.39) | KDM4EALDH1A1GAAHPGDSMN1; SMN2 | |
| SCHEMBL22874879 | 0.79 | PARP1 (0.34) | KDM4EALDH1A1GAAHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1865940-A2 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Applera Corporation (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2006102243-A2 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | APPLERA CORPORATION (US) | 2006-09-28 | — | — | WO | claimed |
| WO-2024039829-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| US-20240025860-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (HK) | 2024-01-25 | — | — | US | disclosed |
| US-20230399308-A1 | 2,6-DISUBSTITUTED PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-09 | — | — | US | disclosed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| US-11780820-B2 | 2,6-disubstituted pyridine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-10 | — | — | US | disclosed |
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230312564-A1 | AROMATIC RING-LACTAM COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| WO-2023187182-A1 | PYRAZOLOPYRAZINONE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2023-10-05 | — | — | WO | disclosed |
| US-7531546-B2 | Spiro-substituted pyrrolo[2,3-D]pyrimidines as cathepsin inhibitors | NOVARTIS AG (CH) | 2009-05-12 | — | — | US | disclosed |
| US-7531546-B2 | Spiro-substituted pyrrolo[2,3-D]pyrimidines as cathepsin inhibitors | NOVARTIS AG (CH) | 2009-05-12 | — | — | US | disclosed |
| US-7528148-B2 | Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| WO-2008032164-A2 | BENZIMIDAZOLONE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1592426-B1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | US | disclosed |
| WO-2004076455-A1 | SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES | NOVARTIS AG (CH) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004069256-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780844-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | KDM4E 3874/4885ALDH1A1 1784/4885GAA 82/4885 |
| US-20230312564-A1 | AROMATIC RING-LACTAM COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, WASF2 | KDM4E 2100/4885ALDH1A1 2123/4885GAA 2559/4885 |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | KDM4E 2746/4885ALDH1A1 1243/4885GAA 1170/4885 |
| US-20070072853-A1 | Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof | RB1, CYP2C19, ADRB3 | KDM4E 2030/4885ALDH1A1 165/4885GAA 1933/4885 |
| US-20230399308-A1 | 2,6-DISUBSTITUTED PYRIDINE DERIVATIVE | CNR1, CNR2, CRHR1 | KDM4E 2092/4885ALDH1A1 267/4885GAA 4733/4885 |
| US-20240025860-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | ACE2, ACE, SARS1 | KDM4E 3320/4885ALDH1A1 2946/4885GAA 818/4885 |
| US-11780820-B2 | 2,6-disubstituted pyridine derivative | CNR1, CNR2, CRHR1 | KDM4E 2092/4885ALDH1A1 267/4885GAA 4733/4885 |
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | KDM4E 1816/4885ALDH1A1 2049/4885GAA 2243/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | KDM4E 2058/4885ALDH1A1 1806/4885GAA 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.